These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 9458463)
1. Lipid-lowering with statins and fibrinolytic parameters. Jovin IS; Heidinger K; Taborski U; Muller-Berghaus G Eur Heart J; 1997 Sep; 18(9):1516. PubMed ID: 9458463 [No Abstract] [Full Text] [Related]
2. Efficacy of low-density-lipoprotein lowering with statins. Seidel D; Cremer P Lancet; 1994 Sep; 344(8923):683. PubMed ID: 7915367 [No Abstract] [Full Text] [Related]
3. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. Rosenson RS; Tangney CC JAMA; 1998 May; 279(20):1643-50. PubMed ID: 9613915 [TBL] [Abstract][Full Text] [Related]
4. C-reactive protein and lipids may respond differently to statins. Black DM Curr Atheroscler Rep; 2003 Jan; 5(1):9. PubMed ID: 12562533 [No Abstract] [Full Text] [Related]
5. Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan. Lin TH; Voon WC; Yen HW; Huang CH; Su HM; Lai WT; Sheu SH Kaohsiung J Med Sci; 2006 Jun; 22(6):257-65. PubMed ID: 16793562 [TBL] [Abstract][Full Text] [Related]
6. Statins as immunomodulatory drugs. Górski A; Kasprzycka M; Nowaczyk M; Wierzbicki P; Korczak-Kowalska G; Jezak P; Kłosowska D; Ekiert A; Kłodos K Adv Exp Med Biol; 2001; 495():283-8. PubMed ID: 11774580 [No Abstract] [Full Text] [Related]
7. Implications of 4S evidence on baseline lipid levels. Ravnskov U Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7603244 [No Abstract] [Full Text] [Related]
13. [The role of HDL in the prevention of cardiovascular events]. Paragh G; Harangi M Orv Hetil; 2001 Jan; 142(3):121-6. PubMed ID: 11217160 [TBL] [Abstract][Full Text] [Related]
14. [Kidney and statins]. Moulin B; Caillard S Ann Endocrinol (Paris); 2001 Feb; 62(1 Pt 2):121-7. PubMed ID: 11240414 [TBL] [Abstract][Full Text] [Related]
15. [Statins: similarities and differences in the pharmacological, clinical and laboratory aspects]. Motti C; Gnasso A; Cortese C Ann Ital Med Int; 2000; 15(1):96-102. PubMed ID: 10842898 [TBL] [Abstract][Full Text] [Related]
16. Effects of ezetimibe/simvastatin combination on metabolic parameters. Filippatos TD; Elisaf MS Int J Cardiol; 2016 Jan; 202():273-4. PubMed ID: 26408840 [No Abstract] [Full Text] [Related]
17. Lipid-lowering agents may fight cancer by denying it LDL. Firestone RA Int J Cancer; 2006 Nov; 119(10):2497. PubMed ID: 16858681 [No Abstract] [Full Text] [Related]
18. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Alsheikh-Ali AA; Karas RH Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402 [TBL] [Abstract][Full Text] [Related]
19. Statins and the kidney. Wheeler DC Curr Opin Nephrol Hypertens; 1998 Sep; 7(5):579-84. PubMed ID: 9818207 [TBL] [Abstract][Full Text] [Related]
20. Statins and the assessment of endothelial function. Lee KW; Felmeden DC; Lip GY J Intern Med; 2002 May; 251(5):452-3; author reply 453-4. PubMed ID: 11982746 [No Abstract] [Full Text] [Related] [Next] [New Search]